Global Amlodipine Besylate Tablets Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Amlodipine Besylate Tablets Market Research Report 2024
Amlodipine besylate is a dihydropyridine calcium channel antagonist, which can selectively inhibit cell membrane calcium ion channels, act on smooth muscle cells and cardiomyocytes, effectively regulate intracellular calcium levels, and enable normal physiological functions. Maintain, thereby dilate the coronary blood vessels and the blood vessels of the whole body, and lower blood pressure. Clinically, it is generally used to treat hypertensive coronary heart disease and essential hypertension. Amlodipine can be used alone or in combination with other antihypertensive drugs, chronic stable angina and variant angina.
According to Mr Accuracy reports’s new survey, global Amlodipine Besylate Tablets market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Amlodipine Besylate Tablets market research.
Key manufacturers engaged in the Amlodipine Besylate Tablets industry include China Resources Double-Crane Pharmaceutical, Pfizer, North China Pharmaceutical, AstraZeneca, Sanofi, Roche, Bristol-Myers Squibb, Yangtze River Pharmaceutical and Shanghai Shyndec Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Amlodipine Besylate Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Amlodipine Besylate Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amlodipine Besylate Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

China Resources Double-Crane Pharmaceutical
Pfizer
North China Pharmaceutical
AstraZeneca
Sanofi
Roche
Bristol-Myers Squibb
Yangtze River Pharmaceutical
Shanghai Shyndec Pharmaceutical
Jingfeng Pharmaceutical
Segment by Type
5 Milligrams
10 Milligrams
Hospital
Pharmacy
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Amlodipine Besylate Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Amlodipine Besylate Tablets market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Amlodipine Besylate Tablets market research.
Key manufacturers engaged in the Amlodipine Besylate Tablets industry include China Resources Double-Crane Pharmaceutical, Pfizer, North China Pharmaceutical, AstraZeneca, Sanofi, Roche, Bristol-Myers Squibb, Yangtze River Pharmaceutical and Shanghai Shyndec Pharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Amlodipine Besylate Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Amlodipine Besylate Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amlodipine Besylate Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
China Resources Double-Crane Pharmaceutical
Pfizer
North China Pharmaceutical
AstraZeneca
Sanofi
Roche
Bristol-Myers Squibb
Yangtze River Pharmaceutical
Shanghai Shyndec Pharmaceutical
Jingfeng Pharmaceutical
Segment by Type
5 Milligrams
10 Milligrams
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Amlodipine Besylate Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
